# Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Study · id `cardio:ct-nct02642159` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02642159](<https://clinicaltrials.gov/study/NCT02642159>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02642159

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 413 participants.

## Technical summary

Registry record NCT02642159. Randomized; no masking; primary purpose treatment. Start 2016-03-15 (registry gives no type); primary completion 2017-03-22 (actual). Results posted on 2018-05-01.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 413 participants (enrolled count; ClinicalTrials.gov record NCT02642159, source copy `cardio:ctgov-nct02642159-2018-05-01`, retrieved 2026-10-31)
- Start date: 2016-03-15 (registry gives no type) (ClinicalTrials.gov record NCT02642159, source copy `cardio:ctgov-nct02642159-2018-05-01`, retrieved 2026-10-31)
- Primary completion: 2017-03-22 (actual) (ClinicalTrials.gov record NCT02642159, source copy `cardio:ctgov-nct02642159-2018-05-01`, retrieved 2026-10-31)
- Completion: 2017-05-15 (actual) (ClinicalTrials.gov record NCT02642159, source copy `cardio:ctgov-nct02642159-2018-05-01`, retrieved 2026-10-31)
- Results first posted: 2018-05-01 (ClinicalTrials.gov record NCT02642159, source copy `cardio:ctgov-nct02642159-2018-05-01`, retrieved 2026-10-31)
- Countries: United States; Australia; Brazil; Finland; Germany; Israel; Italy; Kuwait; Lebanon; Norway; Sweden; Switzerland; Türkiye; United Arab Emirates; United Kingdom (ClinicalTrials.gov record NCT02642159, source copy `cardio:ctgov-nct02642159-2018-05-01`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02642159-2018-05-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
- Condition: Dyslipidemia
- Intervention (Drug): Alirocumab
- Intervention (Drug): Statins
- Intervention (Drug): Ezetimibe
- Intervention (Drug): Fenofibrate
- Intervention (Drug): Nicotinic acid
- Intervention (Drug): Omega-3 fatty acids
- Intervention (Drug): Antihyperglycemic Drug
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY
- Collaborator: Regeneron Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)
- Registry intervention name matches this record: Statins (`cardio:statins`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial (`cardio:pubmed-29436756`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol (`cardio:pubmed-32035487`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e33de44e8de85a35ed01b3c3ebe9e5d1cf03e5c3ff76e9cd861b8e84d2d2ea2f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
